An Institution-Specific Hypofractionated Radiation Therapy Regimen in the Treatment of Central and Ultracentral Non-small Cell Lung Cancer
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2025.08.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von M Judy Lubas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fox Chase Cancer Center, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiation Dose Hypofractionation. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Institutes of Health Clinical Center.
Abstract (Originalsprache)
PURPOSE/OBJECTIVES: While stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy (HFRT) is routinely used to treat inoperable early-stage non-small lung cancer (esNSCLC) patients with peripheral tumors, SBRT or HFRT for central (cenT) and ultracentral tumors (UCT) remains controversial. To treat patients with tumors located within 0-2 cm of critical mediastinal structures (CMSTs), we employ an institution specific hypofractionated radiation regimen (isHFRT) with a biologically effective dose (BED) of 98.59 using 17 fractions to a dose of 6987 cGy. METHODS: We conducted a single-institution retrospective review of patients with esNSCLC treated with this isHFRT between 2011 and 2020, evaluating both tumor control rates and rates of treatment related toxicity. RESULTS: Of the 31 patients evaluated, 61.3% of patients had UCTs while 38.7% had cenTs. At 1- and 3 years, local control (LC) was noted to be 93.5% and 86.8% respectively. 1-year overall survival (OS) was 74.2% for all comers, 75.0% for patients with cenTs and 73.7% for patients with UCTs (p = 0.70). 3-year OS was 20.8%. Only 22.6% of patients who expired at 1-year experienced disease progression. At 12 months, adverse event free survival (AEFS) was 67.7%. While 25.8% (n = 8) of patients experienced a Grade 2 (G2) or greater toxicity, no patient experienced a G2 or greater cardiotoxicity. Only 1 patient (3.3%) experienced a Grade 5 toxicity (fatal hemoptysis 12-months following treatment). Review of the case demonstrated that the maximum tracheobronchial tree dose had been exceeded. CONCLUSIONS: Our isHFRT for patients with esNSCLC proves a safe and effective treatment for medically inoperable esNSCLC patients with cenTs and UCTs with comparable rates of toxicity when compared to prior studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fox Chase Cancer Center, Philadelphia, PA, USA.
- Lake Erie College of Osteopathic Medicine, Erie, PA, USA.
- Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Sameera.kumar@fccc.edu.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Institutes of Health Clinical Center
Zitieren
APA
Lubas, M. J., Vata, A., Fredette, J., Edelman, M. J., & Kumar, S. (2025). An Institution-Specific Hypofractionated Radiation Therapy Regimen in the Treatment of Central and Ultracentral Non-small Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.08.018
Vancouver
Lubas MJ, Vata A, Fredette J, Edelman MJ, Kumar S. An Institution-Specific Hypofractionated Radiation Therapy Regimen in the Treatment of Central and Ultracentral Non-small Cell Lung Cancer. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.08.018
BibTeX
@article{Lubas2025,
author = {Lubas, M Judy and Vata, Albi and Fredette, Jordan and Edelman, Martin J and Kumar, Sameera},
title = {An Institution-Specific Hypofractionated Radiation Therapy Regimen in the Treatment of Central and Ultracentral Non-small Cell Lung Cancer},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2025.08.018}
}
EUVIMED